Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 133

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 133
---
 things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA. Such off -labeluses are common across medical specialties. Physicians may believe that such off -labeluses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer’s communications on the subject of off -labeluse of their products. 84

DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE Executive Officers and Directors The following table sets forth information regarding our executive officers and directors, including their ages as of April [•], 2025:

| Name                         |     | Age |     | Position                             |
| BOARD OF DIRECTORS           |     |     |     |                                      |
| George Tidmarsh, M.D., Ph.D. |     |  65 |     | Chairman and Director                |
| James Rolke                  |     |  56 |     | Director and Chief Executive Officer |
| Jennifer Carver, BSN, MBA    |     |  71 |     | Director                             |
| Jess Roper                   |     |  60 |     | Director                             |
| Lakhmir Chawla, M.D.         |     |  54 |     | Director                             |
| EXECUTIVE OFFICERS           |     |     |     |                                      |
| James Rolke                  |     |  56 |     | Director and Chief Executive Officer |
| Chester S. Zygmont, III      |     |  44 |     | Chief Financial Officer              |

Our Director and Executive Officers George Tidmarsh, M.D., Ph.D. — Chairman.Dr. Tidmarsh has been Chairman of the Company since its inception in May 2020. Dr. Tidmarsh received his M.D. and Ph.D. from Stanford University, where he also completed his fellowship training in Pediatric Oncology and Neonatology and is currently Adjunct Faculty of Pediatrics and Neonatology since 2018. He served as clinical faculty at Stanford for a number of years after his fellowship prior to devoting his full time to clinical research and development in order to bring new treatments through the FDA approval process. Since 2018 Dr. Tidmarsh has served as a director and chairman of audit committee of Lucile Pack